Skip to main content

Advertisement

Log in

The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report the reproducibility, sensitivity, specificity, and predictive value of home monitoring for disease activity in neovascular age-related macular degeneration (ARMD).

Methods

Participants were trained to complete three separate home monitoring tasks, designed to identify subtle changes in visual function that may indicate increasing neovascular ARMD disease activity. These included measurement of near acuity and assessments of environmental distortion and overall visual function. The need for repeat intra-vitreal injection, as predicted by home monitoring, was compared to standard clinical assessment involving ETDRS distance acuity, slit lamp examination, and spectral domain ocular coherence tomography.

Results

Although all participants were able to complete the home monitoring tasks, the reproducibility of each of the three tasks was modest. Cohen’s kappa was 0.118 (p = 0.54) for the comparison of the outcome of the home monitoring exercise with the gold standard of hospital assessment to determine disease activity. The sensitivity of the home monitoring exercise was 33.3 % (95 % CI 15.2–51.4) and the specificity was 77.8 % (95 % CI 61.8–93.8).

Conclusions

This study suggests that current tests of visual function, which are readily completed at home, cannot replace traditional clinic-based assessments for neovascular ARMD disease activity. Instead, such tests are likely to remain complementary to standard assessment in clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Brown C, Xing W, Wormald R (2010) Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) 24(11):1692–1699

    Article  Google Scholar 

  2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65

    Article  PubMed  Google Scholar 

  3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431

    Article  CAS  PubMed  Google Scholar 

  4. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U et al (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94(1):2–13

    Article  CAS  PubMed  Google Scholar 

  5. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43–58

    Article  CAS  PubMed  Google Scholar 

  6. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388–1398

    Article  Google Scholar 

  7. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7):1399–1411

    Article  Google Scholar 

  8. Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76(5):378–382

    Article  Google Scholar 

  9. Bartko JJ (1966) The intra-class correlation coefficient as a measure of reliability. Psychol Rep 19(1):3–11

    Article  CAS  PubMed  Google Scholar 

  10. Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20(1):37–46

    Article  Google Scholar 

  11. Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK (2014) Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond) 28(7):788–796

    Article  CAS  Google Scholar 

  12. Mathew R, Sivaprasad S (2012) Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration. Eye 26:389–393

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Wang YZ, He YG, Mitzel G, Zhang S, Bartlett M (2013) Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci 54(8):5497–5505

    Article  PubMed Central  PubMed  Google Scholar 

  14. Weymouth AE, McKendrick AM (2012) Shape perception is altered by normal aging. Invest Ophthalmol Vis Sci 53(6):3226–3233

    Article  PubMed  Google Scholar 

  15. Trevino R, Kynn MG (2008) Macular function surveillance revisited. Optometry 79(7):397–403

    Article  PubMed  Google Scholar 

  16. Fletcher DC, Schuchard RA (2006) Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Optom Vis Sci 83:178–189

    Article  PubMed  Google Scholar 

  17. Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E et al (2003) Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 110(5):966–970

    Article  PubMed  Google Scholar 

  18. The AREDS2-HOME Study Research Group, Chew WC, Clemons TE, Bressler SB, Elman MJ, Danis RP et al (2014) Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 121(2):535–544

    Article  PubMed Central  Google Scholar 

  19. Das R, Shi Y, Silvestri G, Chakravarty U (2009) Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina 29:1013–1018

    Article  PubMed  Google Scholar 

  20. Querques G, Querques L, Rafaeli O, Canoui-Poitrine F, Bandello F, Souied EH (2011) Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci 52(9):7012–7018

    Article  CAS  PubMed  Google Scholar 

  21. Kaiser PK, Wang YZ, He YG, Weisberger A, Wolf S, Smith CH (2013) Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: results of a pilot study. Retina 33(9):1863–1870

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This project was supported by an award from the Biomedical Health Research Centre Problem Solving Fund (PSF87).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin McKibbin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McKibbin, M., Baker, L., Baxter, P. et al. The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD. Graefes Arch Clin Exp Ophthalmol 253, 1479–1483 (2015). https://doi.org/10.1007/s00417-014-2839-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-014-2839-4

Keywords

Navigation